Principal component analysis (PCA) indicated that ELAVL2-high GBM patients were clearly separated from ELAVL2-low patients, which was further supported by the box plots using PC1 and PC2 values, indicating a significant difference in the transcriptomic profiles along the PC1 dimension. This evidence concerns the gene ELAVL2 and glioblastoma.